Fmr LLC Anavex Life Sciences Corp. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Fmr LLC holds 13,286 shares of AVXL stock, worth $73,073. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,286

Previous 1,745 661.38%

Holding current value

$73,073

Previous $8,000 600.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$3.39 - $5.02 $39,123 - $57,935	11,541 Added 661.38%	13,286 $56,000
Q1 2024 May 13, 2024	SELL	$4.55 - $6.75 $34,134 - $50,638	-7,502 Reduced 81.13%	1,745 $8,000
Q4 2023 Feb 13, 2024	BUY	$5.04 - $9.95 $42,315 - $83,540	8,396 Added 986.6%	9,247 $86,000
Q3 2023 Nov 13, 2023	SELL	$6.55 - $9.37 $7,277 - $10,410	-1,111 Reduced 56.63%	851 $5,000
Q2 2023 Aug 11, 2023	BUY	$7.66 - $9.5 $4,304 - $5,339	562 Added 40.14%	1,962 $15,000
Q1 2023 May 11, 2023	BUY	$8.32 - $11.75 $2,812 - $3,971	338 Added 31.83%	1,400 $11,000
Q4 2022 Feb 13, 2023	SELL	$7.65 - $14.43 $4,873 - $9,191	-637 Reduced 37.49%	1,062 $9,000
Q3 2022 Nov 10, 2022	SELL	$8.9 - $12.86 $394,679 - $570,289	-44,346 Reduced 96.31%	1,699 $17,000
Q2 2022 Aug 12, 2022	BUY	$7.31 - $12.84 $2,178 - $3,826	298 Added 0.65%	46,045 $461,000
Q1 2022 May 13, 2022	BUY	$9.74 - $17.69 $445,215 - $808,609	45,710 Added 123540.54%	45,747 $563,000
Q4 2021 Feb 14, 2022	SELL	$16.88 - $23.31 $42,200 - $58,275	-2,500 Reduced 98.54%	37 $1,000
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $41,915 - $64,169	2,492 Added 5537.78%	2,537 $45,000
Q2 2021 Aug 13, 2021	BUY	$10.16 - $28.86 $457 - $1,298	45 New	45 $1,000

Others Institutions Holding AVXL

# of Institutions

152

Shares Held

26.5M

Call Options Held

674K

Put Options Held

811K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $429M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account